XAMS
DSFIR
Market cap30bUSD
Oct 27, Last price
108.95EUR
1D
0.37%
1Q
30.67%
IPO
-8.94%
Name
DSM-Firmenich AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
Related entities
Subsidiaries (19)
CAMPUS S.R.L.
ANH Solutions AG
Animal Nutrition & Health Denmark A/S
CAMPUS SCANDINAVIA AS
DSM Finance B.V.
DSM Food Specialties B.V.
DSM Nutritional Products
DSM Nutritional Products AG
DSM Venturing B.V.
dsm-firmenich Switzerland AG
FIRMENICH BELGIUM
FIRMENICH ET CIE
FIRMENICH GRASSE
FIRMENICH INTERNATIONAL SA
FIRMENICH PRODUCTIONS PARTICIPATIONS SAS
FIRMENICH SA
PT FIRMENICH AROMATICS INDONESIA
Key people
Thomas Leysen
Non-Executive Independent Chairman of the Board · since 2023
Patrick Firmenich
Non-Executive Vice Chairman of the Board · since 2023
Ralf Schmeitz
Chief Financial Officer, Member of the Executive Committee · since 2023
Nikeisha van Sleeuwen
Chief Human Resources Officer, Member of the Executive Committee · since 2026
Emmanuel Butstraen
Business Unit President Perfumery & Beauty, Chief Operating Officer, Member of the Executive Committee · since 2025
Dimitri de Vreeze
Chief Executive Officer, Member of the Executive Committee · since 2023
Philip Eykerman
Business Unit President Health, Nutrition & Care and Head of M&A, Member of the Executive Committee · since 2023
Ivo Lansbergen
Business Unit President Animal Nutrition & Health, Member of the Executive Committee · since 2023
Patrick Niels
Business Unit President Taste, Texture & Health, Member of the Executive Committee · since 2023
Sarah Reisinger
Chief Science & Research Officer, Member of the Executive Committee · since 2023
Jane Sinclair
Chief Legal, Risk, Regulatory and Compliance Officer, Member of the Executive Committee · since 2023
Mieke Van de Capelle
Chief Human Resources Officer, Member of the Executive Committee · since 2023
Andre Pometta
Non-Executive Director · since 2023
Sze Cotte-Tan
Non-Executive Independent Director · since 2023
Antoine Firmenich
Non-Executive Independent Director · since 2023
Carla Mahieu
Non-Executive Independent Director · since 2023
Erica Mann
Non-Executive Independent Director · since 2023
John Ramsay
Non-Executive Independent Director · since 2023
Richard Ridinger
Non-Executive Independent Director · since 2023
Frits van Paasschen
Non-Executive Independent Director · since 2023
Headquarters & legal address
Wurmisweg 576
Kaiseraugst, AG 4303
CH
Kaiseraugst, AG 4303
CH
Previous name
Danube AG
Other language
DSM-Firmenich Ltd
Other language
DSM-Firmenich SA
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||